Hatch-Waxman and Defective Generic Drug Labels: The Disjunction Between Federal Drug Safety Law and State Warning Defect Law (Part II)
In an earlier post I outlined a regulatory anomaly regarding liability for defective drug labels. Hatch-Waxman expedited entry of generics medications into the market, by relieving generic-brand manufacturers of the need to conduct further testing. Concomitantly, the statute placed control of the contents of the drug label in the hands of the original recipient of […]

